CN110240557B - 吡咯烷酰胺衍生物及其用途 - Google Patents

吡咯烷酰胺衍生物及其用途 Download PDF

Info

Publication number
CN110240557B
CN110240557B CN201910170019.3A CN201910170019A CN110240557B CN 110240557 B CN110240557 B CN 110240557B CN 201910170019 A CN201910170019 A CN 201910170019A CN 110240557 B CN110240557 B CN 110240557B
Authority
CN
China
Prior art keywords
compound
chf
alkyl
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910170019.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN110240557A (zh
Inventor
金传飞
陈康智
张英俊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong HEC Pharmaceutical Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of CN110240557A publication Critical patent/CN110240557A/zh
Application granted granted Critical
Publication of CN110240557B publication Critical patent/CN110240557B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201910170019.3A 2018-03-08 2019-03-07 吡咯烷酰胺衍生物及其用途 Active CN110240557B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810192198 2018-03-08
CN2018101921986 2018-03-08

Publications (2)

Publication Number Publication Date
CN110240557A CN110240557A (zh) 2019-09-17
CN110240557B true CN110240557B (zh) 2023-05-09

Family

ID=67845842

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910170019.3A Active CN110240557B (zh) 2018-03-08 2019-03-07 吡咯烷酰胺衍生物及其用途

Country Status (8)

Country Link
US (1) US11225460B2 (https=)
EP (1) EP3762364B1 (https=)
JP (1) JP7405756B2 (https=)
CN (1) CN110240557B (https=)
AU (1) AU2019230883B2 (https=)
CA (1) CA3092747A1 (https=)
SG (1) SG11202008543RA (https=)
WO (1) WO2019170115A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240317681A1 (en) * 2020-07-07 2024-09-26 Sunshine Lake Pharma Co., Ltd. Pyrrolidine amide derivative salt and use thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113896671B (zh) * 2020-07-07 2023-06-09 广东东阳光药业有限公司 吡咯烷酰胺衍生物的盐及其用途
CN113896670B (zh) * 2020-07-07 2023-06-09 广东东阳光药业有限公司 吡咯烷酰胺衍生物的盐及其用途
CN114573491B (zh) * 2020-12-01 2023-12-08 广东东阳光药业股份有限公司 吡咯烷酰胺衍生物的制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026826A1 (en) * 2002-09-20 2004-04-01 F. Hoffmann-La Roche Ag 4-pyrrolidino-phenyl-benzyl ether derivatives
WO2005040108A1 (en) * 2003-10-15 2005-05-06 Newron Pharmaceuticals S.P.A. Prolinamide derivatives as sodium and/or calcium channel blockers or selective mao-b inhibitors
WO2006138475A2 (en) * 2005-06-16 2006-12-28 Jenrin Discovery Mao-b inhibitors useful for treating obesity
CN1993319A (zh) * 2004-08-02 2007-07-04 弗·哈夫曼-拉罗切有限公司 作为maob抑制剂的苄氧基衍生物
CN101559053A (zh) * 1999-10-11 2009-10-21 科学研究和应用咨询公司 5-元杂环衍生物、其制备及其作为药物的用途
CN104684894A (zh) * 2012-10-02 2015-06-03 默克专利股份有限公司 吡咯烷类

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
WO2000033788A2 (en) 1998-12-11 2000-06-15 American Biogenetic Sciences Inc. Substituted nitrogen heterocyclic compounds and therapeutic uses thereof
US7501528B2 (en) 2005-03-15 2009-03-10 Hoffmann-La Roche Inc. Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives
BRPI0821026A2 (pt) 2007-12-19 2015-06-16 Newron Pharmaceutical S P A Derivados de alfa-minoamidas úteis no tratamento de transtornos psiquiátricos
EP3601255A1 (en) 2017-03-21 2020-02-05 AbbVie Deutschland GmbH & Co. KG Proline amide compounds and their azetidine analogues carrying a specifically substituted benzyl radical

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101559053A (zh) * 1999-10-11 2009-10-21 科学研究和应用咨询公司 5-元杂环衍生物、其制备及其作为药物的用途
WO2004026826A1 (en) * 2002-09-20 2004-04-01 F. Hoffmann-La Roche Ag 4-pyrrolidino-phenyl-benzyl ether derivatives
CN1681777A (zh) * 2002-09-20 2005-10-12 弗·哈夫曼-拉罗切有限公司 作为maob抑制剂的吡咯烷酮衍生物
WO2005040108A1 (en) * 2003-10-15 2005-05-06 Newron Pharmaceuticals S.P.A. Prolinamide derivatives as sodium and/or calcium channel blockers or selective mao-b inhibitors
CN1993319A (zh) * 2004-08-02 2007-07-04 弗·哈夫曼-拉罗切有限公司 作为maob抑制剂的苄氧基衍生物
WO2006138475A2 (en) * 2005-06-16 2006-12-28 Jenrin Discovery Mao-b inhibitors useful for treating obesity
CN104684894A (zh) * 2012-10-02 2015-06-03 默克专利股份有限公司 吡咯烷类

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240317681A1 (en) * 2020-07-07 2024-09-26 Sunshine Lake Pharma Co., Ltd. Pyrrolidine amide derivative salt and use thereof

Also Published As

Publication number Publication date
CN110240557A (zh) 2019-09-17
WO2019170115A1 (en) 2019-09-12
AU2019230883A1 (en) 2020-09-24
EP3762364A1 (en) 2021-01-13
JP7405756B2 (ja) 2023-12-26
US20210053918A1 (en) 2021-02-25
AU2019230883B2 (en) 2024-02-01
JP2021515019A (ja) 2021-06-17
EP3762364B1 (en) 2023-08-23
SG11202008543RA (en) 2020-10-29
US11225460B2 (en) 2022-01-18
CA3092747A1 (en) 2019-09-12
EP3762364A4 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
CN110240557B (zh) 吡咯烷酰胺衍生物及其用途
CN111333648B (zh) 8-取代的芳香环乙烯基黄嘌呤衍生物及其用途
CN110437205A (zh) 吡啶烯基哌啶衍生物及其用途
CN111004214B (zh) 吡啶酰基哌啶衍生物及其用途
CN112300165B (zh) 8-取代的苯乙烯基黄嘌呤衍生物及其用途
WO2020125779A1 (en) 8-substituted styryl xanthine derivatives and uses thereof
CN111187251B (zh) 吡啶酰基哌啶衍生物及其用途
CN112010818B (zh) 吗啉酰胺衍生物及其用途
CN111187252A (zh) 吡啶酰基氮杂螺庚烷衍生物及其用途
CN108912029B (zh) 含氮杂环酰胺衍生物及其用途
CN111072604B (zh) α-氨基酰胺衍生物及其用途
CN111072676B (zh) 含氮稠合三环衍生物及其用途
CN111018856B (zh) 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN109734712B (zh) 芳基或杂芳基取代的吡咯烷酰胺衍生物及其用途
CN118063445A (zh) 吡咯烷酰胺衍生物及其用途
CN118063444A (zh) 氮杂环丁烷酰胺衍生物及其用途
CN110845402A (zh) 吡啶亚甲基哌嗪衍生物及其用途
CN111072675A (zh) 含氮稠合三环衍生物及其用途
WO2021097781A1 (zh) 吡啶亚甲基哌啶衍生物及其用途
CN110938064B (zh) N-取代哌啶酰胺衍生物及其用途
CN111072663B (zh) 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN109761892B (zh) 含氮杂环基团取代的酰胺衍生物及其用途
CN110922408B (zh) 3H-[1,2,3]三唑并[4,5-d]嘧啶-5-胺衍生物及其用途
HK40036563B (en) Pyrrolidineamide derivatives and uses thereof
HK40036563A (en) Pyrrolidineamide derivatives and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province

Patentee after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd.

Address before: 523808 No. 1 Industrial North Road, Songshan Industrial Park, Songshan, Guangdong, Dongguan, Hubei

Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd.

CP03 Change of name, title or address